Unleashing the power of next generation ADC cancer treatments
View Pipeline
Pipeline
AmMax Bio is developing a robust oncology pipeline of Antibody Drug Conjugates (ADCs), with its lead program, AMB-104, incorporating clinically validated components and supported by compelling preclinical data.